[Available carbapenems: Properties and differences].
Carbapenems are β-lactam antibiotics endowed with a broader spectrum, activity and resistance to β-lactamases than other β-lactams. Due to their qualities, these antibiotics are crucial in empirical therapy, in the monotherapy of several severe hospital-acquired infections -and even that of some community-acquired infections- as well as in the directed therapy of infections due to multiresistant Gram-negative bacteria. All the available carbapenems have a similar spectrum, although there are significant differences in their antimicrobial activity, which in the long run determines the clinical indications of each carbapenem. The spectrum of ertapenem does not cover eminently nosocomial pathogens such as Pseudomonas aeruginosa and Acinetobacter spp., and hence this antibiotic is indicated in community-acquired infections requiring hospital treatment. In contrast, doripenem shows greater intrinsic activity than other carbapenems in extended spectrum beta-lactamase-producing enterobacteria and AmpC P. aeruginosa, Acinetobacter spp. and other non-fermentative and anaerobic microorganisms. Additionally, like the remaining carbapenems, doripenem has adequate pharmacokinetic characteristics and a favorable safety profile.
Universidad de Salamanca, España.
María José Fresnadillo
MJ
Martínez
María Inmaculada García
MI
García
Enrique García
EG
Sánchez
José Elías García
JE
Sánchez
D000005:Abdomen; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000737:chemistry / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D001426:Bacterial Proteins / Q000145:classification / Q000378:metabolism; D001682:Biological Availability; D015780:Carbapenems / Q000009:adverse effects / Q000737:chemistry / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002473:Cell Wall / Q000187:drug effects; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D017714:Community-Acquired Infections / Q000188:drug therapy; D003428:Cross Infection / Q000188:drug therapy; D004347:Drug Interactions; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D014018:Tissue Distribution; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000145:classification / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; D001618:beta-Lactamases; C063912:carbapenemase